Welcome to our new website! If this is the first time you are logging in on the new site, you will need to reset your password. Please contact us at email@example.com if you need assistance.
Your membership opens the door to free learning resources on demand. Check out the Member Knowledge Center for free webcasts, publications and online courses.
Hear from leaders around the globe as they share insights about their experiences and lessons learned throughout their certification journey.
RAPS recognizes that the current situation in Ukraine impacts our members and customers on many levels. If you are directly impacted by the current situation in the region and are challenged to meet your deadlines or obligations to RAPS, please reach out to firstname.lastname@example.org so that we can defer those challenges. Your health and safety are paramount to us.
Posted 08 October 2012 | By Ansis Helmanis,
The European Medicines Agency (EMA) published on 5 October 2012 the first list of EU member states responsible for monitoring the safety of specific active substances across the EU.
In effect, each listed country will be responsible for monitoring specific medicinal products that have been approved for marketing in more than one EU member state through either the national, mutual recognition or decentralized procedures.
The monitoring data that each country will rely on will be the European pharmacovigilance system (EudraVigilance) established in 2010 by Regulation 1235/2010. According to EMA, the list will be updated "on a regular basis" to add further substances, countries not as yet included, and possibly "co-leader" countries if needed to ensure that drug products are adequately monitored.
Read all Breaking News from RegLink
Tags: List, Eudravigilance, Latest News, safety, EU, pharmacovigilance